Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone

Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) to the Bone: A Whole Body MRI Study

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study is aimed to compare whole body MRI (WB-MRI) with Bone Scintigraphy (BS) and Computerized Tomography (CT) scans in patients receiving treatment for metastatic castration-resistant prostate cancer to the bone. This is a monocentric, prospective observational study.

Who May Be Eligible (Plain English)

Who May Qualify: - Histological diagnosis of castration-resistant prostate cancer, - Single or multiple bone metastases, - Life expectancy of over 6 months, - No current active malignancy other than prostate cancer, - Provision of written willing to sign a consent form. Who Should NOT Join This Trial: - Absolute contraindication to WB-MRI, CT or BS, - Radical treatment of sole site of metastatic disease (e.g. Cyberknife to solitary metastatic lesion), - Psychological, familial, sociological or geographical conditions that would hamper compliance with the study protocol; such conditions are to be discussed with the patient as part of the willing to sign a consent form process. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Histological diagnosis of castration-resistant prostate cancer, * Single or multiple bone metastases, * Life expectancy of over 6 months, * No current active malignancy other than prostate cancer, * Provision of written informed consent. Exclusion Criteria: * Absolute contraindication to WB-MRI, CT or BS, * Radical treatment of sole site of metastatic disease (e.g. Cyberknife to solitary metastatic lesion), * Psychological, familial, sociological or geographical conditions that would hamper compliance with the study protocol; such conditions are to be discussed with the patient as part of the informed consent process.

Treatments Being Tested

PROCEDURE

Imaging evaluation

each patient will undergo imaging with CT, BS and WB-MRI at each study timepoint

Locations (1)

IEO Istituto Europeo di Oncologia
Milan, Italy